ZBIO - $42 target priceZenas BioPharma, Inc.BATS:ZBIOSimeonNikolaev-investInsider activity in ZBIO is among the strongest we've seen in 2026. The combination of massive CEO buyouts, a strong cash position, and an impending FDA approval in the coming months makes this stock extremely attractive. The potential upside to the $42 target price seems conservative if FDA approval is successful.